REPATHA (evolocumab subcutaneous injection) Patient Assistance Program
Don’t let the high cost of brand PCSK9 inhibitor disrupt your cholesterol and cardiovascular risk reduction care. We help eligible patients access Repatha (evolocumab subcutaneous injection) for as little as $69.95 per month through the manufacturer’s Patient Assistance Program.
- Clear & Transparent Pricing
- Paperwork & Doctor-Coordination
- Comprehensive Support: From Application to Entire Journey
- Annual Re-certification And Refills Management
- Medicare Part D Patients Accepted
HIPAA Compliant
BBB Accredited
Secure Website
Key Takeaways:
- Repatha (evolocumab) is FDA-approved to reduce the risk of myocardial infarction, stroke, and coronary revascularization in adults with established cardiovascular disease, as adjunct therapy to lower LDL cholesterol in adults and pediatric patients (≥10 years) with primary hyperlipidemia (including heterozygous familial hypercholesterolemia), and in patients with homozygous familial hypercholesterolemia. Anti-PCSK9 monoclonal antibody — subcutaneous injection every 2 weeks (140 mg) or monthly (420 mg).
- Without assistance, brand Repatha costs commonly run approximately $560–$650 per month (substantially reduced since price cuts in recent years).
- Through AffordMyPrescriptions, qualifying patients can access Repatha for a flat $69.95 per month.
- Other PCSK9 inhibitors: Praluent (alirocumab — similar mechanism, also monoclonal antibody). Inclisiran (Leqvio — siRNA against PCSK9, twice-yearly SC injection after loading). Generic statins very cheap first-line: atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin. Ezetimibe (Zetia generic) — adjunct cholesterol absorption inhibitor. Generic bempedoic acid combinations (Nexletol — brand, ATP citrate lyase inhibitor for statin-intolerant patients). Bile acid sequestrants (cholestyramine, colesevelam — generic). Newer: Leqvio (twice-yearly), Repatha and Praluent (every-2-week or monthly), oral PCSK9 inhibitors in development.
What is Repatha Prescription Assistance Program?
The Repatha Patient Assistance Program is a manufacturer-sponsored initiative that helps eligible patients access Repatha (used to reduce cardiovascular events in established CVD, lower LDL cholesterol in primary hyperlipidemia and familial hypercholesterolemia) at little or no cost when they meet specific income, insurance, and clinical criteria. The program is free to apply for, but the enrollment process involves detailed applications, cardiology or lipid specialist coordination, lipid panel documentation, supporting documentation, and ongoing renewal — which can be overwhelming when you are managing high cardiovascular risk.
At AffordMyPrescriptions, our Patient Advocates handle the entire Repatha PAP enrollment for a flat $69.95 per month. We complete the application, coordinate with your prescriber for required medical documentation (typically including documented statin failure or intolerance, baseline lipid levels, and ASCVD history), follow up with the manufacturer’s program until approval, manage your refills, and handle annual re-certification — so you never face a gap in your Repatha PCSK9 inhibitor therapy.
AffordMyPrescriptions eliminates that burden. For a flat $69.95 per month, our Patient Advocates handle every step of your Repatha enrollment — from the initial application through ongoing refills and annual re-enrollment — so you never face a gap in your cardiovascular risk reduction treatment.
Pharmacy Price Comparison
- Without assistance, Repatha costs hundreds of dollars per month at retail and specialty pharmacies. Discount cards and pharmacy coupons offer some relief, but they don't come close to what a Patient Assistance Program provides if you qualify. The table below compares typical retail pricing across major pharmacies to what you'd pay with our Repatha advocacy service:
| Pharmacy(With Coupon) | PrIce (30-Day)* | You Save W/ Us |
|---|---|---|
| Walgreens | ~$640/mo | Save substantially |
| CVS Pharmacy | ~$650/mo | Save substantially |
| Walmart | ~$580/mo | Save substantially |
| Specialty pharmacy | ~$560/mo | Save substantially |
| Praluent (alt PCSK9 mAb) | ~$580/mo | Alt PCSK9 inhibitor |
*Retail prices are estimates based on public data and vary by pharmacy. Coupon prices from GoodRx and SingleCare as of April 2026. AffordMyPrescriptions Advocacy Service bypasses pharmacy pricing entirely by using the manufacturer’s assistance program to secure your Repatha — independent of dosage or retail price.
Our Pricing:
$69.95 Per month
1 Medications
$79.95 Per Month
2 Medications
$89.95 Per Month
3 Medications
$99.95 Per Month
4+ Medications
Why choose us For Your Repatha Prescription Program?
The Repatha Patient Assistance Program is free to apply and provides medication at no cost if approved. But the process involves detailed applications, prescriber coordination, documentation, and ongoing management — applications that are commonly delayed or denied when paperwork is incomplete. Our $69.95 per month covers full advocacy: applications, doctor coordination, documentation, refill management, and re-enrollment — so you focus on your health, not paperwork. Generic high-intensity statin therapy plus ezetimibe is foundational and very inexpensive — PCSK9 inhibitors are reserved for patients who cannot achieve LDL goals with maximally tolerated statin and ezetimibe.
Enroll
Complete a simple eligibility form so our team can determine if you may qualify for medication assistance programs.
We Advocate
Our specialists help gather documentation, complete applications, and coordinate with program providers.
Receive Medication
Once approved, you may receive your medication through the assistance program while we help manage ongoing paperwork and renewals.
Discount Coupons vs. Patient Assistance Programs
Many patients try discount cards first. Here’s why the Patient Assistance Program through AffordMyPrescriptions is the better long-term solution for Repatha:
Limitations of Coupons
Prices fluctuate — savings aren’t guaranteed month-to-month
Copay accumulators may prevent savings from counting toward your deductible
Coupon cards expire and require constant renewal
- Still $560–$650 per month even with the best discount
Cannot be used with Medicare, Medicaid, or government insurance
Advantages of PAP Through Us
- Fixed $69.95/month — never changes regardless of retail price
- No expiration — continuous access as long as you qualify
- Medication supplied directly through the assistance program
- We manage all paperwork, refills, and annual renewals
- Medicare Part D patients accepted
DO YOU QUALIFY?
Eligibility is generally determined by annual household income and insurance status. Most programs follow guidelines that include limits of up to $40,000 for individuals, $60,000 for couples, and $100,000 for larger families. Because requirements vary by program and household, we encourage you to contact AffordMyPrescriptions directly so we can review your specific situation and determine if you qualify for Repatha assistance.
- You Are A U.S. Citizen Or Legal Resident
- You Have A Valid Repatha Prescription From A Licensed U.S. Healthcare Provider
- You Are Uninsured, Underinsured, Or A Medicare Part D Beneficiary
- You Have Recently Experienced A Change In Financial Circumstances That Affects Your Ability To Pay
Understanding Repatha:
Repatha is a fully human monoclonal antibody that binds and inactivates PCSK9 (proprotein convertase subtilisin/kexin type 9) — a protein that degrades LDL receptors. Blocking PCSK9 allows more LDL receptors to remain on hepatocytes, dramatically increasing LDL clearance from the blood. Achieves 50–60% additional LDL reduction beyond statin therapy. Outcome data show meaningful cardiovascular event reduction.
How Repatha works:
Atherosclerotic cardiovascular disease (ASCVD) is driven primarily by elevated LDL cholesterol. Statins reduce LDL effectively for most patients, but some need additional reduction — especially in established CVD, familial hypercholesterolemia, or statin intolerance.
PCSK9 normally binds and degrades hepatic LDL receptors, limiting LDL clearance. Repatha is a monoclonal antibody that binds circulating PCSK9 — prevents PCSK9 from degrading LDL receptors — increases LDL receptor density on hepatocytes — increases LDL clearance. Adds 50–60% LDL reduction on top of statin therapy. The FOURIER trial demonstrated cardiovascular event reduction in established ASCVD patients.
Form and use:
Repatha subcutaneous injection. 140 mg every 2 weeks via SureClick autoinjector or 1 mL prefilled syringe, OR 420 mg once monthly via the Pushtronex on-body infusor or three 140 mg injections within 30 minutes. Injection in abdomen, thigh, or upper arm. Refrigerate; allow to reach room temperature 30 minutes before injection.
Generic availability:
No biosimilar Repatha. Other PCSK9 inhibitors: Praluent (alirocumab — anti-PCSK9 mAb, similar mechanism and dosing), Leqvio (inclisiran — siRNA against PCSK9 in hepatocytes, twice-yearly SC after loading). Foundational therapy: generic statins (atorvastatin, rosuvastatin, simvastatin, pravastatin, lovastatin, fluvastatin, pitavastatin) — first-line, very cheap. Generic ezetimibe (Zetia) — cholesterol absorption inhibitor, often added when statin alone insufficient. Generic bempedoic acid (Nexletol — brand) — for statin-intolerant patients. Generic bile acid sequestrants: cholestyramine, colestipol, colesevelam. Other: omega-3 ethyl esters (icosapent ethyl — Vascepa, brand reduces CV events; mineral oil-based generic less effective). Lifestyle: Mediterranean or DASH diet, regular aerobic exercise, weight management, smoking cessation, BP and diabetes management.
Warnings:
Hypersensitivity reactions (urticaria, anaphylaxis — rare), injection site reactions, nasopharyngitis, upper respiratory tract infection, influenza, back pain, myalgia (less than statin-related; check creatine kinase if severe), neurocognitive effects (no clear evidence of harm in trials despite early concerns), new-onset diabetes (less than statins, but reported). Limited data in pregnancy and lactation — IgG antibody crosses placenta — discuss with prescriber if planning pregnancy. Drug interactions minimal vs small-molecule lipid agents.
FAQ (Frequently Asked Questions)
How Much Does Repatha Cost Without Insurance?
Brand Repatha $560–$650 per month following manufacturer price reductions in recent years. Generic high-intensity statins (atorvastatin 40-80 mg, rosuvastatin 20-40 mg) cost $5–$15 per month — foundational first-line therapy.
What is the difference between Repatha and statins?
Statins reduce LDL by inhibiting HMG-CoA reductase (cholesterol synthesis). Repatha reduces LDL by preventing PCSK9-mediated degradation of LDL receptors — additive effect on top of statin. Statins are first-line, very cheap, with substantial outcome evidence. Repatha is added when statin (with or without ezetimibe) doesn’t achieve LDL goal in high-risk patients — adds 50–60% further LDL reduction.
Why aren't generic statins tried before Repatha?
They typically are — high-intensity statin therapy (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) is foundational. Insurance and guidelines typically require documented maximally tolerated statin (or documented statin intolerance) and often added ezetimibe before approving PCSK9 inhibitors.
What is the difference between Repatha and Leqvio (inclisiran)?
Both target PCSK9. Repatha is a monoclonal antibody — injected every 2 weeks or monthly. Leqvio is an siRNA that silences PCSK9 production in hepatocytes — injected twice yearly after loading. Leqvio’s less frequent dosing is convenient but cardiovascular outcomes data are less mature than Repatha’s. Cost is similar.
Can Repatha be used in pediatric patients?
Yes — approved for pediatric patients ≥10 years with heterozygous familial hypercholesterolemia, and for homozygous familial hypercholesterolemia. Dosing same as adults.
How long does it take for Repatha to start working?
LDL reduction begins within days; maximal effect typically by 4 weeks. Repeat lipid panel about 4–8 weeks after starting to confirm response. Cardiovascular event reduction emerges over months to years.
Does Repatha cause memory or thinking problems?
No clear evidence of meaningful neurocognitive harm in large randomized trials despite early concerns. EBBINGHAUS substudy of FOURIER found no significant cognitive difference vs placebo.
What happens if my Repatha Patient Assistance Program application is denied?
We help explore Praluent (alirocumab) copay programs (alternative PCSK9 monoclonal), Leqvio (inclisiran) brand assistance (twice-yearly dosing), generic high-intensity statin therapy optimization, generic ezetimibe addition, bempedoic acid for statin-intolerant patients, foundation aid (Patient Access Network, Patient Advocate Foundation, FH Foundation for familial hypercholesterolemia, NeedyMeds), and Medicare Part D Extra Help.
Take Control of Your Medication Costs
Cardiovascular risk reduction with PCSK9 inhibition should not be derailed by cost. Generic high-intensity statins remain foundational very cheap first-line. Our Repatha advocacy team is ready to verify your eligibility, complete the manufacturer application on your behalf, and manage your prescription through approval, delivery, and renewal — for a flat $69.95 per month. If we cannot help you access Repatha through a Patient Assistance Program, you are not charged. Call (833) 556-2729 or check your eligibility online today.
Submit Enrollment Form
Start free by filling out a simple online form.
Receive Welcome Call
Our specialist will contact you for a quick welcome call.
We Manage The Process
Our team handles everything, so you can focus on your health.